Herbal Remedies, Nutraceuticals, and Dietary Supplements for COVID-19 Management: An Update
Vivek P. Chavda,Aayushi Patel,Disha Vihol,Darsh D. Vaghasiya,Khandu Muhammed Saad Bashir Ahmed,Kushal U. Trivedi,Divyang J. Dave +6 more
Reads0
Chats0
TLDR
In this article , the authors evaluated the effectiveness of traditional Chinese medicine (TCM) and nutraceutical drugs against the Coronavirus 2 (SARS-CoV-2) pandemic.Abstract:
Currently, the world is facing a Coronavirus pandemic with a grave deficiency of specific therapy for Coronavirus Disease (COVID-19). Moreover, scientists attempt to discover the most refined approach to prevent this condition. Regarding COVID-19 infection, herbal medicines with immunomodulatory effects may offer patients a promising preventive treatment option. Several ayurvedic and Traditional Chinese Medicine (TCM) are effective during this worrisome Coronavirus pandemic i.e. Tinospora cordifolia (Willd.) Miers, Withania somnifera (L.) Dunal, Scutellaria baicalensis Georgi, Curcuma longa L. etc. TCM was shown to be utilized with over 90% efficacy when the COVID-19 pandemic broke out in early 2020. In addition to herbal treatments and nutraceutical drugs, dietary supplements such as vitamins and amino acid derivatives also play a significant part in COVID-19 management. Diet can assist in regulating inflammation, while nutraceuticals can aid in the prevention of viral invasion. Functional amino acids (e.g., arginine, cysteine, glutamate, glutamine, glycine, taurine, and tryptophan) and glutathione, which are all abundant in animal-sourced foodstuffs, are crucial for optimum immunity and health in humans and animals. The goal of this article is to thoroughly evaluate recent statistics on the effectiveness of herbal medicines in COVID-19, the antiviral activity of nutraceuticals, and the significance of these results in creating dietary supplements that would enhance innate immunity and contribute as preventive measures against severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2). read more
Citations
More filters
Journal ArticleDOI
SARS‐CoV‐2 variants and vulnerability at the global level
TL;DR: Various variants of SARS‐CoV‐2 surfaced with special emphasis on VOCs that are spreading across the world, as well as several viral mutational impacts and how these modifications alter the properties of the virus are summarized.
Journal ArticleDOI
Therapeutic monoclonal antibodies for COVID-19 management: an update
Vivek P. Chavda,Riddhi Prajapati,Disha Lathigara,Bhumi Nagar,Jay Kukadiya,Elrashdy M. Redwan,Vladimir N. Uversky,Mukesh N. Kher,Patel Rajvi +8 more
TL;DR: This review article provides insights into the basic aspects of monoclonal antibodies for the therapy of COVID-19, as well as its advancement in terms of clinical trial and current approval status.
Journal ArticleDOI
Replicating Viral Vector-Based Vaccines for COVID-19: Potential Avenue in Vaccination Arena
TL;DR: In this article , the authors discuss the potential of replicating viral vectors as vaccine carriers for SARS-CoV-2, which is the third member of human coronavirus (CoV) that is held accountable for the current "coronavirus disease 2019 (COVID-19)" pandemic.
Journal ArticleDOI
Recent review of COVID-19 management: diagnosis, treatment and vaccination
Vivek P. Chavda,Suneetha Vuppu,Toshika Mishra,Sathvika Kamaraj,Aayushi Patel,Nikita Sharma,Zhe S Chen +6 more
TL;DR: In this paper , the authors focused on the complications prevalent during the COVID-19 and post-COVID period and discussed the novel approaches developed for mitigation of the global pandemic.
Journal ArticleDOI
2-Deoxy-D-Glucose and its Derivatives for the COVID-19 Treatment: An Update
Zoufang Huang,Vivek P. Chavda,Lalitkumar K. Vora,Normi D. Gajjar,Vasso Apostolopoulos,Nirav Shah,Zhe-Sheng Chen +6 more
TL;DR: The development process, synthesis, mechanism of viral eradication, and preclinical and clinical development of 2-DG and its derivatives as molecularly targeted therapeutics for COVID-19 treatment are described.
References
More filters
Journal ArticleDOI
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Chaolin Huang,Yeming Wang,Xingwang Li,Lili Ren,Jianping Zhao,Yi Hu,Li Zhang,Guohui Fan,Jiuyang Xu,Xiaoying Gu,Zhenshun Cheng,Ting Yu,Jia'an Xia,Yuan Wei,Wenjuan Wu,Xuelei Xie,Wen Yin,Li Hui,Min Liu,Yan Xiao,Hong Gao,Li Guo,Jungang Xie,Guang-Fa Wang,Rongmeng Jiang,Zhancheng Gao,Qi Jin,Jianwei Wang,Bin Cao +28 more
TL;DR: The epidemiological, clinical, laboratory, and radiological characteristics and treatment and clinical outcomes of patients with laboratory-confirmed 2019-nCoV infection in Wuhan, China, were reported.
Journal ArticleDOI
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Peng Zhou,Xing-Lou Yang,Xian Guang Wang,Ben Hu,Lei Zhang,Wei Zhang,Hao Rui Si,Yan Zhu,Bei Li,Chao Lin Huang,Hui-Dong Chen,Jing Chen,Yun Luo,Hua Guo,Ren Di Jiang,Meiqin Liu,Ying Chen,Xu Rui Shen,Xi Wang,Xiao Shuang Zheng,Kai Zhao,Quanjiao Chen,Fei Deng,Lin Lin Liu,Bing Yan,Fa Xian Zhan,Yan-Yi Wang,Gengfu Xiao,Zhengli Shi +28 more
TL;DR: Identification and characterization of a new coronavirus (2019-nCoV), which caused an epidemic of acute respiratory syndrome in humans in Wuhan, China, and it is shown that this virus belongs to the species of SARSr-CoV, indicates that the virus is related to a bat coronav virus.
Journal ArticleDOI
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
Markus Hoffmann,Hannah Kleine-Weber,Simon Schroeder,Nadine Krüger,Tanja Herrler,Sandra Erichsen,Tobias S. Schiergens,Georg Herrler,Nai Huei Wu,Andreas Nitsche,Marcel A. Müller,Christian Drosten,Christian Drosten,Stefan Pöhlmann +13 more
TL;DR: It is demonstrated that SARS-CoV-2 uses the SARS -CoV receptor ACE2 for entry and the serine protease TMPRSS2 for S protein priming, and it is shown that the sera from convalescent SARS patients cross-neutralized Sars-2-S-driven entry.
Journal ArticleDOI
Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein.
Alexandra C. Walls,Young-Jun Park,M. Alejandra Tortorici,M. Alejandra Tortorici,Abigail Wall,Andrew T. McGuire,Andrew T. McGuire,David Veesler +7 more
TL;DR: It is demonstrating that cross-neutralizing antibodies targeting conserved S epitopes can be elicited upon vaccination, and it is shown that SARS-CoV-2 S uses ACE2 to enter cells and that the receptor-binding domains of Sars- coV- 2 S and SARS S bind with similar affinities to human ACE2, correlating with the efficient spread of SATS among humans.
Journal ArticleDOI
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus.
Wenhui Li,Michael Moore,Natalya Vasilieva,Jianhua Sui,Swee Kee Wong,Michael A. Berne,Mohan Somasundaran,John L. Sullivan,Katherine Luzuriaga,Thomas C. Greenough,Hyeryun Choe,Michael Farzan +11 more
TL;DR: It is found that a soluble form of ACE2, but not of the related enzyme ACE1, blocked association of the S1 domain with Vero E6 cells, indicating that ACE2 is a functional receptor for SARS-CoV.
Related Papers (5)
Awareness of coronavirus disease (COVID-19) pandemic among interns of a tertiary care hospital
Prachi Priya,Mayur S Sherkhane +1 more